# US 2026/0225998 A1 · New compounds for treating streptococcus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0225998 A1
- Document ID: US20260225998A1
- Status: Published application
- Kind: A1
- Application number: 19/151,191
- Filed: 2024-01-26
- Published: 2026-08-06
- Earliest claimed: 2023-01-27
- Assignees: AB2 Therapeutics, S. L.
- Applicants: AB2 Therapeutics, S. L.
- Inventors: Antoni TORRENS JOVER; Domingo GARGALLO VIOLA; Ana María CAAMAÑO MOURE; Ana Virginia LLORENTE FERNÁNDEZ
- Web page: https://patentgrep.com/patent/US20260225998A1

## CPC

- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07D 251/34: Cyanuric or isocyanuric esters
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/351: not condensed with another ring
- A61P 31/04: Antibacterial agents
- C07C 231/08: from amides by reaction at nitrogen atoms of carboxamide groups
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07D 309/04: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 309/06: Radicals substituted by oxygen atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new bactericidal compounds of formula (I) useful against Streptococcus sp. infections, especially against infections of Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus agalactiae. The invention is also directed to the process for the preparation of said bactericidal compounds, to compositions comprising them, and to their use as medicaments.

## Claims

### Claim 1

A compound of general formula (I):
wherein:
R1 is a hydrogen atom, a halogen atom, a branched or unbranched C1-6 alkyl radical or —OR1a;
R1a is a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
R2 is a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
R3 is a hydrogen atom, a branched or unbranched C1-6 alkyl, or —(CH2)m—OR3a;
R3a is a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
R4 is a hydrogen atom, a branched or unbranched C1-6 alkyl, or —(CH2)n—OR4a;
R4a is a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
R5 is a hydrogen atom; a branched or unbranched C1-6 alkyl radical optionally substituted; a halogen atom; a —CN; a C1-6 haloalkyl radical; an optionally substituted —(CH2)r—C3-9 cycloalkyl; an optionally substituted —(CH2)s—C3-9 heterocycloalkyl containing at least one heteroatom selected from N, O or S; an optionally substituted —(CH2)j-aryl; or an optionally substituted —(CH2)i-heteroaryl containing at least one heteroatom selected from N, O or S; all of the optionally substituted radicals being substituted by at least one substituent selected from the group consisting of a hydrogen atom, halogen atom, a branched or unbranched C1-6 alkyl radical, a C1-6 haloalkyl radical, a C1-6 haloalkoxy radical; —CN, —OR5a, —NR5aR5b, NR5aC(O)R5b, —NR5aC(O)NR5bR5c, —C(O)OR5a, —C(O)NR5aR5b, —OCH2CH2OH, and —C(CH3)2OR5a;
R5a, R5b and R5c are each independently a hydrogen atom or branched or unbranched C1-6 alkyl radical;
R6, R7 and R8 are each independently from one another selected from the group consisting of a hydrogen atom, a branched or unbranched C1-6 alkyl radical optionally substituted; a halogen atom; a —CN; a C1-6 haloalkyl radical; an optionally substituted C3-9 cycloalkyl; an optionally substituted C3-9 heterocycloalkyl containing at least one heteroatom selected from N, O or S; an —O—C1-6-alkyl optionally substituted; an —O—C1-6-haloalkyl; an optionally substituted —O—C3-9 cycloalkyl; an optionally substituted —O—C3-9 heterocycloalkyl containing at least one heteroatom selected from N, O or S; all of the optionally substituted radicals being substituted by at least one substituent selected from the group consisting of a hydrogen atom, halogen atom, a branched or unbranched C1-6 alkyl radical, a C1-6 haloalkyl radical, a C1-6 haloalkoxy radical; —CN, —ORa, —NRaRb, NRaC(O)Rb, —C(O)ORa, —C(O)NRaRb, —OCH2CH2OH, and —C(CH3)2ORa;
Ra, and Rb are each independently a hydrogen atom or branched or unbranched C1-6 alkyl radical
R9 is a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
R10 is a hydrogen atom; a branched or unbranched C1-6 alkyl radical optionally substituted; a —CN; a C1-6 haloalkyl radical; an optionally substituted —(CH2)r—C3-9 cycloalkyl; an optionally substituted —(CH2)j-aryl; an optionally substituted —O—C1-6-alkyl; all of the optionally substituted radicals being substituted by at least one substituent selected from the group consisting of a hydrogen atom, halogen atom, a branched or unbranched C1-6 alkyl radical, a C1-6 haloalkyl radical, a C1-6 haloalkoxy radical; —CN, —OR10a, —NR10aR10b, NR10aC(O)R10b, —NR10aC(O)NR10bR10c, —C(O)OR10a, —C(O)NR10aR10b, —OCH2CH2OH, —NR10aS(O)2NR10bR10c, and —C(CH3)2OR10a;
R10a, R10b and R10c are each independently a hydrogen atom or branched or unbranched C1-6 alkyl radical;
n is 0, 1, 2 or 3;
m is 0, 1, 2 or 3;
r is 0, 1, 2 or 3;
s is 0, 1, 2 or 3;
j is 0, 1, 2 or 3;
i is 0, 1, 2 or 3;
wherein the compound of formula (I) is optionally in form of one of the stereoisomers, a racemate or in form of a mixture of at least two of the stereoisomers, in any mixing ratio, or a corresponding salt, co-crystal or prodrug thereof, or a corresponding solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is a hydrogen atom or —OR1a.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R5 is a branched or unbranched C1-6 alkyl radical optionally substituted; or one of the following groups:

### Claim 4 (depends on 1)

The compound according to claim 1 wherein R6, R7 and R8 are each independently from one another selected from the group consisting of a hydrogen atom, and a halogen atom; or a C1-6 haloalkyl radical.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R10 is a hydrogen atom; a branched or unbranched C1-6 alkyl radical optionally substituted.

### Claim 6 (depends on 1)

The compound according to claim 1, with the general formula (Ia) or (Ib):
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in claim 1.

### Claim 7 (depends on 1)

The compound according to claim 1, with the general formula (Ia1) or (Ib1):
wherein R1, R2, R3, R4, R6, R7, R8, R9 and R10 are as defined in claim 1 and R represents —CH2— or —O—.

### Claim 8 (depends on 1)

The compound according to claim 1 selected from:
[1] N-((S)-3-Amino-2-hydroxy-3-oxopropyl)-4-((S)-2-cyclohexyl-1-(4′-fluoro-[1,1′-biphenyl]-4-yl)ethoxy)benzamide;
[2] N-((S)-3-Amino-2-hydroxy-3-oxopropyl)-4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)benzamide;
[3] N-((S)-3-Amino-2-hydroxy-3-oxopropyl)-4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethoxy)benzamide;
[4] N-((S)-3-amino-2-hydroxy-3-oxopropyl)-4-((S)-2-(tetrahydro-2H-pyran-4-yl)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethoxy)benzamide;
[5] (N-((S)-3-amino-2-hydroxy-3-oxopropyl)-4-((S)-3-methyl-1-(4′-(trifluoromethyl)-[1,1′-bipheny]-4-yl)butoxy)benzamide;
[6] N-((S)-3-amino-2-hydroxy-3-oxopropyl)-4-((S)-2-methyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propoxy)benzamide;
[7] N-((S)-3-amino-2-hydroxy-3-oxopropyl)-4-((R)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)benzamide;
[8] 4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)-N-((S)-2-hydroxy-3-(methylamino)-3-oxopropyl)benzamide;
[9] 4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)-N-((S)-3-(dimethylamino)-2-hydroxy-3-oxopropyl)benzamide;
[10] N-((R)-3-amino-2-hydroxy-3-oxopropyl)-4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)benzamide;
[11] N-((R)-3-amino-2-hydroxy-3-oxopropyl)-4-((R)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)benzamide;
[12] N-((R)-4-amino-4-oxobutan-2-yl)-4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethoxy)benzamide;
[13] 4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)-N-((S)-2-hydroxy-3-((2-hydroxyethyl)amino)-3-oxopropyl)benzamide; or
[14] 4-((S)-2-cyclohexyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)ethoxy)-N-((S)-2-hydroxy-3-(hydroxyamino)-3-oxopropyl)benzamide;
or a pharmaceutical acceptable salt, stereoisomer, co-crystal, prodrug or solvate thereof.

### Claim 9 (depends on 1)

A process for the preparation of the compound of general formula (I):
which comprises reacting a compound of formula (XII):
with a compound of formula (XIII):
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in claim 1.

### Claim 10 (depends on 1)

A process for the preparation of a compound of general formula (I):
comprising reacting a compound of general formula (XVIII):
with a compound of formula (XIX):
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in claim 1.

### Claim 11 (depends on 1)

A medicament comprising the compound according to claim 1.

### Claim 12 (depends on 1)

An antibiotic comprising the compound according to claim 1.

### Claim 13 (depends on 12)

A method of treatment or prophylaxis of Streptococcus sp. infections comprising administering an effective amount of the antibiotic of claim 12 to a subject in need thereof.

### Claim 14 (depends on 13)

The method of treatment or prophylaxis according to claim 13, wherein the infection is an infection caused by Streptococcus pneumoniae, Streptococcus pyogenes or Streptococcus agalactiae.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising thea compound according to claim 1 or a pharmaceutically acceptable salt, isomer, co-crystal, prodrug or solvate thereof, and at least a pharmaceutically acceptable carrier, additive, adjuvant or vehicle.
